| Lori S Weber, MD | |
|
1836 South Ave, La Crosse, WI 54601-5429 | |
| (608) 782-7300 | |
| Not Available |
| Full Name | Lori S Weber |
|---|---|
| Gender | Female |
| Speciality | Pediatrics |
| Location | 1836 South Ave, La Crosse, Wisconsin |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1235133976 | NPI | - | NPPES |
| 34553600 | Medicaid | WI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | 41773 (Wisconsin) | Primary |
| Entity Name | Gundersen Clinic Ltd |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1851343115 PECOS PAC ID: 9638082779 Enrollment ID: O20031106000139 |
News Archive
An experimental vaccine prevents the SARS virus from replicating in laboratory mice, according to a new report in the April 1 issue of Nature. Scientists at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID), one of the National Institutes of Health, developed the vaccine. The vaccine was tested in a mouse model of SARS infection recently validated by other NIAID investigators.
Silicon, whether in its elemental form as silicon wafers or in its oxidized form, known as silicon dioxide or silica, is proving to be a valuable material for biomedical nanotechnology, in large part because of the biocompatibility and chemical inertness of these substances.
Malaria is still a deadly disease in tropical and subtropical regions. Every year the disease infects more than 200 million people worldwide, claiming several hundred thousand victims.
BioMarin Pharmaceutical Inc. today announced the initiation of a Phase 1 trial for BMN 673, a poly ADP-ribose polymerase (PARP) inhibitor, for the treatment of patients with advanced hematological malignancies.
Lawrence S. Bloomberg Faculty of Nursing professor, Dr. Diane Doran, was awarded more than $1 million for research that will help protect the safety of over 900,000 Canadians who receive health care services in their homes every day.
› Verified 7 days ago
| Entity Name | Tri-county Memorial Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1124063573 PECOS PAC ID: 4587642418 Enrollment ID: O20040708000696 |
News Archive
An experimental vaccine prevents the SARS virus from replicating in laboratory mice, according to a new report in the April 1 issue of Nature. Scientists at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID), one of the National Institutes of Health, developed the vaccine. The vaccine was tested in a mouse model of SARS infection recently validated by other NIAID investigators.
Silicon, whether in its elemental form as silicon wafers or in its oxidized form, known as silicon dioxide or silica, is proving to be a valuable material for biomedical nanotechnology, in large part because of the biocompatibility and chemical inertness of these substances.
Malaria is still a deadly disease in tropical and subtropical regions. Every year the disease infects more than 200 million people worldwide, claiming several hundred thousand victims.
BioMarin Pharmaceutical Inc. today announced the initiation of a Phase 1 trial for BMN 673, a poly ADP-ribose polymerase (PARP) inhibitor, for the treatment of patients with advanced hematological malignancies.
Lawrence S. Bloomberg Faculty of Nursing professor, Dr. Diane Doran, was awarded more than $1 million for research that will help protect the safety of over 900,000 Canadians who receive health care services in their homes every day.
› Verified 7 days ago
| Entity Name | Gundersen Lutheran Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1376593442 PECOS PAC ID: 2163331414 Enrollment ID: O20130619000254 |
News Archive
An experimental vaccine prevents the SARS virus from replicating in laboratory mice, according to a new report in the April 1 issue of Nature. Scientists at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID), one of the National Institutes of Health, developed the vaccine. The vaccine was tested in a mouse model of SARS infection recently validated by other NIAID investigators.
Silicon, whether in its elemental form as silicon wafers or in its oxidized form, known as silicon dioxide or silica, is proving to be a valuable material for biomedical nanotechnology, in large part because of the biocompatibility and chemical inertness of these substances.
Malaria is still a deadly disease in tropical and subtropical regions. Every year the disease infects more than 200 million people worldwide, claiming several hundred thousand victims.
BioMarin Pharmaceutical Inc. today announced the initiation of a Phase 1 trial for BMN 673, a poly ADP-ribose polymerase (PARP) inhibitor, for the treatment of patients with advanced hematological malignancies.
Lawrence S. Bloomberg Faculty of Nursing professor, Dr. Diane Doran, was awarded more than $1 million for research that will help protect the safety of over 900,000 Canadians who receive health care services in their homes every day.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Lori S Weber, MD 1836 South Ave, La Crosse, WI 54601-5429 Ph: (608) 782-7300 | Lori S Weber, MD 1836 South Ave, La Crosse, WI 54601-5429 Ph: (608) 782-7300 |
News Archive
An experimental vaccine prevents the SARS virus from replicating in laboratory mice, according to a new report in the April 1 issue of Nature. Scientists at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID), one of the National Institutes of Health, developed the vaccine. The vaccine was tested in a mouse model of SARS infection recently validated by other NIAID investigators.
Silicon, whether in its elemental form as silicon wafers or in its oxidized form, known as silicon dioxide or silica, is proving to be a valuable material for biomedical nanotechnology, in large part because of the biocompatibility and chemical inertness of these substances.
Malaria is still a deadly disease in tropical and subtropical regions. Every year the disease infects more than 200 million people worldwide, claiming several hundred thousand victims.
BioMarin Pharmaceutical Inc. today announced the initiation of a Phase 1 trial for BMN 673, a poly ADP-ribose polymerase (PARP) inhibitor, for the treatment of patients with advanced hematological malignancies.
Lawrence S. Bloomberg Faculty of Nursing professor, Dr. Diane Doran, was awarded more than $1 million for research that will help protect the safety of over 900,000 Canadians who receive health care services in their homes every day.
› Verified 7 days ago
Ashley Corinne Logan, D.O. Pediatrics Medicare: Medicare Enrolled Practice Location: 700 West Avenue S, La Crosse, WI 54601 Phone: 608-785-0940 | |
Clayton J Menagh, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 800 West Ave S, La Crosse, WI 54601 Phone: 608-392-9881 | |
Judy L Klevan, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 1836 South Ave, La Crosse, WI 54601 Phone: 608-782-7300 | |
Jennifer C Peterson, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 1836 South Ave, La Crosse, WI 54601 Phone: 608-782-7300 | |
Antoinette M Peters, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 1836 South Ave, La Crosse, WI 54601 Phone: 608-782-7300 | |
Gary R Stiers, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 1836 South Ave, La Crosse, WI 54601 Phone: 608-782-7300 | |
Christen R Chamberland, MD Pediatrics Medicare: Accepting Medicare Assignments Practice Location: 1900 South Ave, La Crosse, WI 54601 Phone: 608-785-0940 |